open access

Vol 13, No 2 (2010)
Original articles
Published online: 2011-05-20
Submitted: 2012-01-23
Get Citation

Detection of melanoma lesions using 131I-IMBA obtained by electrophilic substitution of 131I for metal organic substituent — a preliminary communication

Michał Janczak, Dariusz Nejc, Małgorzata Bieńkiewicz, Anna Płachcińska, Jacek Kuśmierek
Nucl. Med. Rev 2010;13(2):70-75.

open access

Vol 13, No 2 (2010)
Original articles
Published online: 2011-05-20
Submitted: 2012-01-23

Abstract

BACKGROUND: Compounds of N-alkylated benzamide derivatives have been the subject of investigations in the last few decades from the standpoint of their possible application for scintigraphic detection of melanoma. Positive results have been observed in studies on biodistribution when using animal models and the compound IMBA (N-(2-diethylaminoethyl)-3-iodo-4-metoxybenzamide). The present study presents preliminary results of scintigraphic studies in patients with documented melanoma metastases, who were administered 131I-IMBA synthesized by modified labelling procedure (electrophilic substitution of radioactive 131I to metal organic substituent).
MATERIAL AND METHODS: The study was made in three patients with diagnosed melanoma metastases to tissues and organs. To each patient 111 MBq of 131I-IMBA was intravenously administered and whole body scintigraphy was performed 4 and 24 hours post injection of the radiopharmaceutical. Additionally, after 24 hours, SPECT/CT of selected regions of the body was performed.
RESULTS: In 3 patients a total of 20 lesions of increased activity were found (15 were detected previously by other methods, 5 in the head, 4 in thorax, 2 in liver and spleen, 3 in abdomen and 6 in extremities). In the scintigrams performed 4 hours after 131I-IMBA administration, there were found 12 lesions of enhanced accumulation of the radiopharmaceutical. After 24 hours, due to reduction of background activity, there were 8 additional hot lesions detected. The mean activity tumour/background ratio for 20 lesions 4 hours post injection amounted to 1.51 ± 0.64, and the ratio increased to 2.94 ± 2.32 24 hours after administration of a radiopharmaceutical.
CONCLUSIONS: 131I-IMBA preparation, obtained by a modified labelling procedure, enabled detection of metastatic lesions in the patients. This may indicate that there is a possibility of using radioiodinated IMBA (with 123I or 131I) for diagnosis of melanoma in humans. From our results it follows that scintigraphy should be performed 24 hours post injection. Further studies on diagnostic efficacy (sensitivity and specificity) of the method are necessary.
Nuclear Med Rev 2010; 13, 2: 70–75

Abstract

BACKGROUND: Compounds of N-alkylated benzamide derivatives have been the subject of investigations in the last few decades from the standpoint of their possible application for scintigraphic detection of melanoma. Positive results have been observed in studies on biodistribution when using animal models and the compound IMBA (N-(2-diethylaminoethyl)-3-iodo-4-metoxybenzamide). The present study presents preliminary results of scintigraphic studies in patients with documented melanoma metastases, who were administered 131I-IMBA synthesized by modified labelling procedure (electrophilic substitution of radioactive 131I to metal organic substituent).
MATERIAL AND METHODS: The study was made in three patients with diagnosed melanoma metastases to tissues and organs. To each patient 111 MBq of 131I-IMBA was intravenously administered and whole body scintigraphy was performed 4 and 24 hours post injection of the radiopharmaceutical. Additionally, after 24 hours, SPECT/CT of selected regions of the body was performed.
RESULTS: In 3 patients a total of 20 lesions of increased activity were found (15 were detected previously by other methods, 5 in the head, 4 in thorax, 2 in liver and spleen, 3 in abdomen and 6 in extremities). In the scintigrams performed 4 hours after 131I-IMBA administration, there were found 12 lesions of enhanced accumulation of the radiopharmaceutical. After 24 hours, due to reduction of background activity, there were 8 additional hot lesions detected. The mean activity tumour/background ratio for 20 lesions 4 hours post injection amounted to 1.51 ± 0.64, and the ratio increased to 2.94 ± 2.32 24 hours after administration of a radiopharmaceutical.
CONCLUSIONS: 131I-IMBA preparation, obtained by a modified labelling procedure, enabled detection of metastatic lesions in the patients. This may indicate that there is a possibility of using radioiodinated IMBA (with 123I or 131I) for diagnosis of melanoma in humans. From our results it follows that scintigraphy should be performed 24 hours post injection. Further studies on diagnostic efficacy (sensitivity and specificity) of the method are necessary.
Nuclear Med Rev 2010; 13, 2: 70–75
Get Citation

Keywords

melanoma; aminoalkyl-iodobenzamides; radioiodinated IMBA

About this article
Title

Detection of melanoma lesions using 131I-IMBA obtained by electrophilic substitution of 131I for metal organic substituent — a preliminary communication

Journal

Nuclear Medicine Review

Issue

Vol 13, No 2 (2010)

Pages

70-75

Published online

2011-05-20

Bibliographic record

Nucl. Med. Rev 2010;13(2):70-75.

Keywords

melanoma
aminoalkyl-iodobenzamides
radioiodinated IMBA

Authors

Michał Janczak
Dariusz Nejc
Małgorzata Bieńkiewicz
Anna Płachcińska
Jacek Kuśmierek

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl